KMT2D and neoplasm: A KMT2D deficiency leads to reduced phosphoinositide-3-kinase-interacting protein 1 expression and increased phosphorylated AKT, accelerating tumor growth in NSCLC by activating the PI3K/AKT pathway and upregulating SOX2 expression (209).